"id","bcCategories","studyDesignRationale","studyEstimands","label","description","name","uuid:ID","studyInvestigationalInterventions","documentVersion"
"StudyDesign_1","[]","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","[]","","The main design for the study","Study Design 1","d3ff0d86-87ba-4662-be5d-448574f1c9d2","[]",""
